A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas

References

• Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006;118:152–169.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30:729–747.
   PubMed Web of Science ®Google Scholar
• Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26:1045–1060.
   PubMed Web of Science ®Google Scholar
• Garmhausen D, Hagemann T, Bieber T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013;68:498–506.
   PubMed Web of Science ®Google Scholar
• Watson W, Kapur S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):S4.
   PubMedGoogle Scholar
• Wollina U. Microbiome in atopic dermatitis. Clin Cosmet Investig Dermatol. 2017;10:51–56.
   PubMed Web of Science ®Google Scholar
• Kabashima K, Otsuka A, Nomura T. Linking air pollution to atopic dermatitis. Nat Immunol. 2016;18:5–6.
   PubMed Web of Science ®Google Scholar
• Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112:S118–S127.
   PubMed Web of Science ®Google Scholar
• Farajzadeh S, Esfandiarpour I, Sedaghatmanesh M, et al. Epidemiology and clinical features of atopic dermatitis in Kerman, a desert area of Iran. Ann Dermatol. 2014;26:26–34.
   PubMed Web of Science ®Google Scholar
• Darlenski R, Kazandjieva J, Hristakieva E, et al. Atopic dermatitis as a systemic disease. Clin Dermatol. 2014;32:409–413.
   PubMed Web of Science ®Google Scholar
• Hjuler KF, Bottcher M, Vestergaard C, et al. Increased prevalence of coronary artery disease in severe psoriasis and severe atopic dermatitis. Am J Med. 2015;128:1325–1334.
   PubMed Web of Science ®Google Scholar
• Wohl Y, Wainstein J, Bar-Dayan Y. Atopic dermatitis in Israeli adolescents - a large retrospective cohort study. Acta Derm Venereol. 2014;94:695–698.
   PubMed Web of Science ®Google Scholar
• Romano-Zelekha O, Graif Y, Garty BZ, et al. Trends in the prevalence of asthma symptoms and allergic diseases in Israeli adolescents: results from a national survey 2003 and comparison with 1997. J Asthma. 2007;44:365–369.
   PubMed Web of Science ®Google Scholar
• Mohammad Y, Tabbah K, Mohammad S, et al. International study of asthma and allergies in childhood: phase 3 in the Syrian Arab Republic. East Mediterr Health J. 2010;16:710–716.
   PubMedGoogle Scholar
• Rahimi Rad MH, Hejazi ME, Behrouzian R. Asthma and other allergic diseases in 13-14-year-old schoolchildren in Urmia, Iran. [corrected]. East Mediterr Health J. 2007;13:1005–1016.
   PubMedGoogle Scholar
• Behbehani NA, Abal A, Syabbalo NC, et al. Prevalence of asthma, allergic rhinitis, and eczema in 13- to 14-year-old children in Kuwait: an ISAAC study. International Study of Asthma and Allergies in Childhood. Ann Allergy Asthma Immunol. 2000;85:58–63.
   PubMed Web of Science ®Google Scholar
• Al-Riyami BM, Al-Rawas OA, Al-Riyami AA, et al. A relatively high prevalence and severity of asthma, allergic rhinitis and atopic eczema in schoolchildren in the Sultanate of Oman. Respirology. 2003;8:69–76.
   PubMed Web of Science ®Google Scholar
• Sabry EY. Prevalence of allergic diseases in a sample of Taif citizens assessed by an original Arabic questionnaire (phase I) A pioneer study in Saudi Arabia. Allergol Immunopathol (Madr). 2011;39:96–105.
   PubMed Web of Science ®Google Scholar
• Alzolibani AA. Impact of atopic dermatitis on the quality of life of Saudi children. Saudi Med J. 2014;35:391–396.
   PubMed Web of Science ®Google Scholar
• Mozaffari H, Pourpak Z, Pourseyed S, et al. Quality of life in atopic dermatitis patients. J Microbiol Immunol Infect. 2007;40:260–264.
   PubMedGoogle Scholar
• Al Robaee AA, Shahzad M. Impairment quality of life in families of children with atopic dermatitis. Acta Dermatovenerol Croat. 2010;18:243–247.
   PubMed Web of Science ®Google Scholar
• Al Shobaili HA. The impact of childhood atopic dermatitis on the patients’ family. Pediatr Dermatol. 2010;27:618–623.
   PubMed Web of Science ®Google Scholar
• Kemp AS. Cost of illness of atopic dermatitis in children: a societal perspective. Pharmacoeconomics. 2003;21:105–113.
   PubMed Web of Science ®Google Scholar
• Li AW, Yin ES, Antaya RJ. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review. JAMA Dermatol. 2017;153:1036–1042
   PubMed Web of Science ®Google Scholar
• Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26:1176–1193.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70:338–351.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116–132.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327–349.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71:1218–1233.
   PubMed Web of Science ®Google Scholar
• Breuer K, Braeutigam M, Kapp A, et al. Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology (Basel). 2004;209:314–320.
   PubMed Web of Science ®Google Scholar
• Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186:23–31.
   PubMed Web of Science ®Google Scholar
• Werfel T, Schwerk N, Hansen G, et al. The diagnosis and graded therapy of atopic dermatitis. Dtsch Arztebl Int. 2014;111:509–520.
   PubMed Web of Science ®Google Scholar
• Luger T, De Raeve L, Gelmetti C, et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur J Dermatol. 2013;23:758–766.
   PubMedGoogle Scholar
• Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135:597–606.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol. 2007;157:954–959.
   PubMed Web of Science ®Google Scholar
• Hoeger PH, Lee KH, Jautova J, et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. Br J Dermatol. 2009;160:415–422.
   PubMed Web of Science ®Google Scholar
• Lübbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7:121–131.
   PubMed Web of Science ®Google Scholar
• Kaufmann R, Bieber T, Helgesen AL, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy. 2006;61:375–381.
   PubMed Web of Science ®Google Scholar
• Fowler J, Johnson A, Chen M, et al. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis. 2007;79:65–72.
   PubMed Web of Science ®Google Scholar
• Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology (Basel). 2002;205:271–277.
   PubMed Web of Science ®Google Scholar
• Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110:e2.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Ho V, Ferrandiz C, et al. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22:1290–1301.
   PubMed Web of Science ®Google Scholar
• Gollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol. 2008;158:1083–1093.
   PubMed Web of Science ®Google Scholar
• McKenna SP, Whalley D, de Prost Y, et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venerol. 2006;20:248–254.
   PubMed Web of Science ®Google Scholar
• Staab D, Kaufmann R, Brautigam M, et al. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents’ quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol. 2005;16:527–533.
   PubMed Web of Science ®Google Scholar
• Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51:515–525.
   PubMed Web of Science ®Google Scholar
• Huang X, Xu B. Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis. Dermatology. 2015;231:41–49.
   PubMed Web of Science ®Google Scholar
• Paller AS, Lebwohl M, Fleischer AB Jr, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005;52:810–822.
   PubMed Web of Science ®Google Scholar
• Billich A, Aschauer H, Aszodi A, et al. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269:29–35.
   PubMed Web of Science ®Google Scholar
• Weiss HM, Fresneau M, Moenius T, et al. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Drug Metab Dispos. 2008;36:1812–1818.
   PubMed Web of Science ®Google Scholar
• Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child. 2003;88:969–973.
   PubMed Web of Science ®Google Scholar
• Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol. 2005;53:602–609.
   PubMed Web of Science ®Google Scholar
• Grassberger M, Steinhoff M, Schneider D, et al. Pimecrolimus – an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004;13:721–730.
   PubMed Web of Science ®Google Scholar
• Lynde C, Barber K, Claveau J, et al. Canadian practical guide for the treatment and management of atopic dermatitis. J Cutan Med Surg. 2005;8(Suppl 5):1–9.
   PubMedGoogle Scholar
• Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med. 1997;337:816–821.
   PubMed Web of Science ®Google Scholar
• Luger T, Boguniewicz M, Carr W, et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26:306–315.
   PubMed Web of Science ®Google Scholar
• Langley RG, Luger TA, Cork MJ, et al. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology (Basel). 2007;215 (Suppl 1):27–44.
   PubMedGoogle Scholar
• Siegfried EC, Jaworski JC, Kaiser JD, et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol. 2001;144:507–513.
   PubMed Web of Science ®Google Scholar
• Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2009;124:R19–R28.
   PubMed Web of Science ®Google Scholar
• Grzanka A, Zebracka-Gala J, Rachowska R, et al. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp Dermatol. 2012;21:184–188.
   PubMed Web of Science ®Google Scholar
• Jensen JM, Scherer A, Wanke C, et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy. 2012;67:413–423.
   PubMed Web of Science ®Google Scholar
• Aschoff R, Schmitt J, Knuschke P, et al. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011;20:832–836.
   PubMed Web of Science ®Google Scholar
• Cury Martins J, Martins C, Aoki V, et al. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015;CD009864.
   PubMed Web of Science ®Google Scholar
• Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol. 2004;150:554–562.
   PubMed Web of Science ®Google Scholar
• Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109:539–546.
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005;330:516.
   PubMed Web of Science ®Google Scholar
• Luger TA, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat. 2004;15:169–178.
   PubMedGoogle Scholar
• Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000;136:999–1006.
   PubMed Web of Science ®Google Scholar
• Ring J, Abraham A, de Cuyper C, et al. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a >2000 patient study. J Eur Acad Dermatol Venereol. 2008;22:195–203.
   PubMed Web of Science ®Google Scholar
• Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15. quiz 16–18.
   PubMed Web of Science ®Google Scholar
• Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931–936.
   PubMed Web of Science ®Google Scholar
• Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol. 2011;165:808–814.
   PubMed Web of Science ®Google Scholar
• Gollnick H, Luger T, Freytag S, et al. StabiEL: stabilization of skin condition with Elidel–a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid. J Eur Acad Dermatol Venereol. 2008;22:1319–1325.
   PubMed Web of Science ®Google Scholar
• Fleischer AB, Jr., Abramovits W, Breneman D, et al. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J Dermatolog Treat. 2007;18:151–157.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol. 1998;102:637–644.
   PubMed Web of Science ®Google Scholar
• Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44:S58–S64.
   PubMed Web of Science ®Google Scholar
• Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44:S47–S57.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol. 2001;44:S28–S38.
   PubMed Web of Science ®Google Scholar
• Chapman MS, Schachner LA, Breneman D, et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2005;53:S177–S185.
   PubMed Web of Science ®Google Scholar
• Reitamo S, Rustin M, Harper J, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008;159:942–951.
   PubMed Web of Science ®Google Scholar
• Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol. 2001;44:S65–S72.
   PubMed Web of Science ®Google Scholar
• Kawashima M. Quality of life in patients with atopic dermatitis: impact of tacrolimus ointment. Int J Dermatol. 2006;45:731–736.
   PubMed Web of Science ®Google Scholar
• Poole CD, Chambers C, Allsopp R, et al. Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. J Eur Acad Dermatol Venereol. 2009;24:674–678.
   Web of Science ®Google Scholar
• Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4:1–191.
   PubMedGoogle Scholar
• Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr. Dermatol. 2009;26:551–558.
   PubMed Web of Science ®Google Scholar
• Paller AS, Eichenfield LF, Kirsner RS, et al. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics. 2008;122:e1210–e1218.
   PubMed Web of Science ®Google Scholar
• Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatolog Treat. 2010;21:34–44.
   PubMed Web of Science ®Google Scholar
• Breneman D, Fleischer AB Jr, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008;58:990–999.
   PubMed Web of Science ®Google Scholar
• Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008;159:1348–1356.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63:742–750.
   Web of Science ®Google Scholar